CS Paper Radar

APOD: reasoning-guided agentic population ordinary differential equation discovery for pharmacological digital twins

Romain Ferrara, Martin Soucail, Victor Gertner, Adil Moussali, Joris Cocquebert, Sandrine Oziel-Taieb, Julien Nicolas, Florence Gattacceca, Mihaela van der Schaar, Sébastien Benzekry

cs.AI q-bio.QMcs.LGstat.AP ·submitted 2026-10-05 12:33 UTC · v1

Abstract

Establishing ordinary differential equations (ODEs) describing population data is a fundamental part of mathematical modeling in pharmacology, crucial to developing digital twins. However, doing so from sparse, noisy data is a slow, expert-driven task. Existing automated methods either search a restricted model space or ignore population inter-individual variability. Here we introduce APOD (Agentic Population ODE Discovery), a language-model agent that iteratively reasons over biological knowledge and fit diagnostics in an open-ended search space to discover a population digital twin (PDT), i.e., a shared ODE system with between-subject variability. On synthetic pharmacokinetic and tumor-dynamics benchmarks, APOD recovered ground-truth structures in 94-100\% of runs, 12-fold faster in median than an established library-based search. On real cohorts it converged to valid structures, and proposed a PDT of radioligand-therapy-induced platelet dynamics that predicts thrombocytopenia from first-cycle data and simulates alternative dosing schedules that lower the predicted risk of toxicity.

Closest papers

Nearest neighbours by meaning across the whole index.

Read Before You Fit: Text-Derived Constraints for Discovering Differential Equations from Noisy Biological Data

cs.AI ·2026-11-15 ·Pronoma Banerjee, Md. Masudur Rahman, Juan P. Wachs
similarity 0.64
Abstract

Large language models are increasingly used for scientific equation discovery. However, most existing methods are strongly data-driven and assume sufficiently clean and representative observations. This assumption is problematic in biological systems, where individual-level measurements are often sparse, noisy, heterogeneous, and expensive to obtain. While the underlying mechanisms are extensively described in scientific text, they are not explicitly used for the LLM based modeling of such systems. We introduce P2C, an agentic framework that translates textual descriptions of biological systems into a typed set of formal constraints, and use these constraints to restrict candidate ordinary differential equation (ODE) structures before numerical fitting. P2C consists of five stages: Text2Constraint extraction, ODE discovery, symbolic verification, parameter fitting, and model scoring. We evaluate P2C on four published ODE systems of acute inflammation and immune regulation, under clean and noisy observations. By progressively degrading the numerical evidence, we isolate when textual domain knowledge contributes beyond regression alone. Across the four systems, adding Text2Constraint reduces the worst form error from 1.397 to 0.499 on clean data and from 13.096 to 1.095 for data perturbed with Gaussian noise of $σ=0.1$; P2C also achieves lower form error and trajectory error than several LLM-based baselines over the tested noise range.

0.23

LifeLong Digital Twin: A Unified Modeling Paradigm and Agent Harness for Event-Driven Lifelong Health State Trajectories

cs.AI q-bio.QM ·2026-10-04 ·Jin Jiang, Sean Yates, Jasper Chong, Raymond Brooks, Alex Lawson +2 more
similarity 0.60
Abstract · 15 pages, 5 figures, 2 tables. Technical report

Human health is a continuous, dynamic trajectory shaped by the cumulative interplay of biological processes, clinical events, behaviors and environmental exposures across the life course. Unifying the full breadth of lifelong health information, including longitudinal records, genetic variation, molecular profiles and environmental histories, is essential for whole-person modeling and remains a major challenge. We introduce LifeLong Digital Twin, a unified, event-driven modeling paradigm that organizes Life Events into daily Health States and accumulates them into Lifelong Health Context. An accompanying Agent Harness incorporates multimodal evidence beyond the language model's textual context. We evaluate four language models across 25 disease endpoints on three tasks: Disease Trajectory Forecasting, Disease Risk Ranking and Multi-horizon Disease Prediction. The approach yields marked gains over the reference condition: model-averaged F1 increases by 22.0% for disease identification in trajectory forecasting and 18.3% for five-year disease outcomes; thyroid-disease F1 reaches 0.669. The framework provides a foundation for whole-person digital twins and research on personalized lifelong disease prevention.

0.20

Intervention-Conditioned Counterfactual Human Digital Twin Generator

cs.LG q-bio.QM ·2026-10-09 ·Saeed Farzi, Sofia Michopoulou, Christopher Kipps, Rahman Attar
similarity 0.57
Abstract

Chronic diseases evolve through long, heterogeneous trajectories shaped by interacting mediators, confounders, and treatment histories. Estimating long-term patient trajectories under alternative interventions is essential for in silico clinical trial design. However, most existing models overlook irregular visit intervals and cross-mediator dependencies, both of which are crucial for reliable long-term longitudinal prediction. Moreover, these models typically focus on outcome prediction rather than generating complete patient-state trajectories. To address these challenges, we propose CHDT, an intervention-conditioned Human Digital Twin generator under standard identification assumptions for multimodal longitudinal trajectory estimation. Its main empirical advantage arises from explicit modeling of irregular visit intervals, while cross-mediator refinement provides additional gains in selected intervention-conditioned settings. Across real-world ADNI and simulator-generated ALPACA cohorts, CHDT shows improved long-horizon patient-state fidelity relative to competing baselines. Ablation results indicate that irregular-time conditioning provides the primary empirical gain, and cross-mediator refinement provides additional improvements.

0.11

A Physiology-Informed Digital Twin Framework for Simulating Liver Health Progression

cs.LG ·2026-08-15 ·Sumaiya Afroz Mila, Sandip Ray
similarity 0.56
Abstract · This paper is under review at IEEE Journal of Biomedical and Health Informatics (JBHI)

We present a physiology-informed digital twin of the human liver designed for longitudinal simulation of liver function and early-stage disease progression. The model, referred to as HEPATWIN, integrates key hepatic processes, including carbohydrate, lipid, and protein metabolism, bilirubin conjugation, bile production, and detoxification, within a unified systems-level framework to generate clinically observable biomarker trajectories. Unlike purely data-driven approaches, HEPATWIN incorporates mechanistic representations of liver physiology and patient-specific inputs such as diet, activity, and baseline biomarkers to simulate disease evolution over time. To ensure consistency with clinical progression patterns, we introduce a stage-transition-driven calibration mechanism that aligns simulated outputs with population-level biomarker distributions across disease stages, including NAFLD, fibrosis, and cirrhosis. Validation using the NIDDK NAFLD dataset demonstrates that HEPATWIN produces longitudinal biomarker estimates within clinically acceptable ranges and can forecast trajectories over multi-year horizons. Furthermore, simulated biomarkers retain sufficient clinical signal to support downstream NASH detection with competitive performance relative to models using ground-truth laboratory data. These results highlight the potential of physiology-informed digital twins for personalized, non-invasive diagnosis and prediction of organ health in general and liver health monitoring in particular.

0.06

DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI Scientists

cs.AI ·2026-10-07 ·Samuel Margolis, Paul Schmiedmayer, Alan Huang, Ethan Chen, Ishan Bhattacharjee +10 more
code/data similarity 0.55
Abstract · 34 pages main text, 92 pages supplementary material; 6 main figures. Project: https://DrugTargetWorld.vercel.app. Code: https://github.com/s…

Drug target discovery requires distinguishing molecules that causally drive disease from those that are merely associated with it. Training and evaluating AI agents to perform this workflow end-to-end is difficult because real world biobanks lack known causal ground truth and participant-level data is access controlled. We introduce DrugTargetWorld, a framework that procedurally generates simulated biobanks, or "worlds," with known but concealed causal structure. Each world contains genotypes, proteins, health records, outcomes, and synthetic magnetic resonance imaging (MRI) for 54,000 participants. Agents must construct a disease phenotype, identify causal driver proteins, infer the beneficial direction of modulation, and optionally conduct virtual 'wet lab' experiments. We evaluated nine agents in 540 episodes across 20 cardiovascular worlds and three experimental budgets. Opus 5 and GPT-5.6 Sol achieved the highest mean composite scores, 39.98 and 35.38 of 100, respectively, and both recovered 64% of causal drivers on average. However, no agent reliably distinguished misleading non-causal proteins, and performance remained limited by the integrative judgments required to connect phenotype construction, causal evidence, and intervention decisions. By making each world's causal structure known to the evaluator but hidden from the agent, DrugTargetWorld turns end-to-end drug target discovery into a scalable training and evaluation problem with verifiable reward.

0.41

MADDIE: Multi-Agent Drug Discovery Engine

cs.AI ·2026-10-12 ·Ye Liu, Reza Averly, Avery Meyer, Frazier N. Baker, Ruoxi Gao +2 more
code/data similarity 0.55
Abstract

Drug discovery remains a resource-intensive and time-consuming process, involving billions of dollars and a decade of development to advance a drug to market. While many in silico tools have accelerated this process, operating them still demands substantial time, effort, and expertise from medicinal chemists. Autonomous systems built on Large Language Models (LLMs) have emerged as a promising solution, yet current designs limit their performance. Existing single-agent systems scale poorly to long-horizon, multi-step, and realistic tasks, whereas multi-agent systems typically execute predefined workflows that cannot capture the iterative, non-linear nature of a real drug discovery campaign. Here, we present MADDIE, a multi-agent drug discovery engine. It comprises a central agent, Orchestrator, and four specialized worker agents: HitIdentifier, LeadOptimizer, Synthesizer, and Evaluator, each representing a critical step in a drug discovery campaign. Under Orchestrator's orchestration and coordination, these worker agents are composed into flexible workflows, enabling MADDIE to adapt its strategy and navigate the drug discovery pipeline end-to-end. Across 50 protein targets, MADDIE produces molecules satisfying key property requirements and their synthesis routes, outperforming existing agentic systems, generative models, and general-purpose LLMs by a wide margin. Our analysis reveals how these agents collaborate and that MADDIE can employ different strategies across targets to achieve the campaign's goal, while still being efficient in time and tokens. Together, they demonstrate MADDIE as a low-cost, effective, and efficient autonomous engine for accelerating drug discovery. Code and dataset is available via https://github.com/ninglab/MADDIE.

0.29

CODA: Cohort- and Drift-aware Foundation Model for Multimodal Clinical Reasoning

cs.AI cs.LG ·2026-10-19 ·Changshuo Liu, Jiaqi Zhu, Wenqiao Zhang, Xiaokui Xiao, Beng Chin Ooi
top venue similarity 0.55
Abstract · Accepted by NeurIPS 2026

Recent advances in multimodal foundation models have demonstrated strong performance across diverse clinical tasks. However, existing approaches predominantly operate at the individual sample level and fail to model the interplay between population-level cohort patterns and patient-specific variation that underlie real-world clinical reasoning. In practice, clinicians routinely reason through patient cohorts sharing similar demographic, physiological, or pathological characteristics, while accounting for patient-specific deviations from the group prototype. Motivated by this gap, we propose CODA, a cohort- and drift-aware foundation model for multimodal clinical reasoning. CODA explicitly integrates cohort structure into the modeling pipeline through two complementary mechanisms: cohort-aware population stratification and drift-aware individual adaptation. In particular, we leverage reinforcement learning to discover clinically meaningful patient cohorts, and further model each patient's deviation from cohort prototypes as a structured drift signal encoding fine-grained individual heterogeneity. These cohort- and drift-aware representations are incorporated into the foundation model to enable reasoning that is simultaneously informed by population-level patterns and sensitive to individual-level variation. Extensive experiments on real-world electronic health record (EHR) benchmarks demonstrate that CODA achieves consistent effectiveness and strong generalizability across diverse clinical tasks, including closed-QA, open-QA, and report generation.

0.27

Large language models as oncology world models

cs.LG cs.AIcs.CL ·2026-11-13 ·Julien Vibert, Jakob Nikolas Kather
code/data similarity 0.54
Abstract · 63 pages (main text 35, Supplementary Information 28), 6 figures, 9 Extended Data figures. Code: https://github.com/julienvibert/llm-oncolog…

Large language models (LLMs) can synthesize cancer patient cases, but their internal representation of oncology, or world model, has not been explored systematically. By only specifying tumor type, we show that LLMs tend to generate similar patients per cancer, with on average 81.0% to 93.2% of a cancer's patients sharing the most frequent value of each baseline feature. By systematically varying patient features in 12 clinical scenarios, we show that they follow biomarker and treatment logic in 29 of 36 model-scenario assessments, against 1 of 12 when previous treatment or frailty matters. Continuing real patient trajectories, an LLM predicted 89.9% 12-month survival, and 79.2% with similar patients as examples, against 72.2% observed. To represent these trajectories, we developed the Clinical State Space, a dynamic representation framework that we also applied to real patients. Despite the limits we show, improved world models may support digital twins, which our framework can evaluate.

0.42